Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.
IPO Date: May 22, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $356.64M
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.00 | 3.83%
Avg Daily Range (30 D): $0.42 | 3.11%
Avg Daily Range (90 D): $0.41 | 3.39%
Institutional Daily Volume
Avg Daily Volume: .38M
Avg Daily Volume (30 D): .34M
Avg Daily Volume (90 D): .34M
Trade Size
Avg Trade Size (Sh.): 64
Avg Trade Size (Sh.) (30 D): 52
Avg Trade Size (Sh.) (90 D): 51
Institutional Trades
Total Inst.Trades: 1,999
Avg Inst. Trade: $2.08M
Avg Inst. Trade (30 D): $1.03M
Avg Inst. Trade (90 D): $.99M
Avg Inst. Trade Volume: .07M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.35M
Avg Closing Trade (30 D): $.98M
Avg Closing Trade (90 D): $.97M
Avg Closing Volume: 78.17K
   
News
Jul 18, 2025 @ 8:56 AM
RNA Therapeutics and RNA Vaccines Market Industry ...
Source: Researchandmarkets.Com
Jun 20, 2025 @ 2:59 PM
Flu RNA Vaccines Market Research Report 2025-2034 ...
Source: Researchandmarkets.Com
Mar 5, 2025 @ 11:00 AM
Synaptics Seeks to Alter the Trajectory of the IoT...
Source: Synaptics Incorporated
Feb 14, 2025 @ 1:30 PM
European Commission Approves CSL and Arcturus Ther...
Source: Prnewswire
Dec 8, 2024 @ 1:00 PM
mRNA Therapeutics Market Size to Hit USD 48.65 Bil...
Source: Sns Insider
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-2.53 $-.52 $-1.11
Diluted EPS $-2.52 $-.52 $-1.1
Revenue $ 143.68M $ 29.38M $ 22.77M
Gross Profit $ $ $
Net Income / Loss $ -68.2M $ -14.08M $ -30.01M
Operating Income / Loss $ -82.08M $ -16.83M $ -33.39M
Cost of Revenue $ $ $
Net Cash Flow $ -71.45M $ -20.08M $ -.15M
PE Ratio    
Splits
Nov 16, 2017:   1:7